Inhibikase Therapeutics (IKT)

Inhibikase Therapeutics (IKT) Financial Statements


Inhibikase Therapeutics Financial Overview

Inhibikase Therapeutics's market cap is currently ―. The company's EPS TTM is $-3.374; its P/E ratio is -0.46; Inhibikase Therapeutics is scheduled to report earnings on August 12, 2024, and the estimated EPS forecast is $-0.67. See an overview of income statement, balance sheet, and cash flow financials.
Sep 23Jun 23Mar 23Dec 22Sep 22
Income Statement-
Total Revenue$ 79.57K$ 116.41K$ 64.52K$ 63.57K$ 0.00
Gross Profit$ 79.57K$ 116.41K$ 64.52K$ 63.57K-
EBIT$ -4.77M$ -6.37M$ -4.65M$ -4.26M$ -4.49M
EBITDA$ -4.76M$ -6.21M$ -4.65M$ -4.25M$ -4.49M
Net Income Common Stockholders$ -4.60M$ -5.95M$ -4.42M$ -4.20M$ -4.49M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 16.83M$ 20.94M$ 25.72M$ 23.05M$ 26.53M
Total Assets$ 17.88M$ 22.35M$ 27.93M$ 24.94M$ 28.58M
Total Debt$ 270.04K$ 297.94K$ 325.01K$ 351.29K$ 374.07K
Net Debt$ -16.56M$ -20.64M$ -25.39M$ -22.70M$ -26.16M
Total Liabilities$ 2.86M$ 2.88M$ 2.84M$ 3.90M$ 3.45M
Stockholders Equity$ 15.02M$ 19.46M$ 25.32M$ 21.04M$ 25.14M
Cash Flow-
Free Cash Flow$ -4.11M$ -4.58M$ -5.97M$ -3.56M$ -5.70M
Operating Cash Flow$ -4.11M$ -4.57M$ -5.97M$ -3.56M$ -5.50M
Investing Cash Flow$ 17.06M$ 2.55M$ -5.84M$ 4.96M$ -20.93M
Financing Cash Flow$ 70.00$ -35.99K$ 8.58M-$ 0.00
Currency in USD

Inhibikase Therapeutics Earnings and Revenue History

Inhibikase Therapeutics Debt to Assets

Inhibikase Therapeutics Cash Flow

Inhibikase Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis